Europska Unija -
hrvatski -
EMA (European Medicines Agency)
kadcyla
roche registration gmbh - trastuzumab emtansin - neoplazme dojki - antineoplastična sredstva - ranog raka dojke (ЕДК)kadcyla je uvedena, kao jedini agent, navodi адъювантного liječenje odraslih bolesnika s her2 pozitivnim ranim rakom dojke, koji su preostali od invazivnog raka dojke i/ili limfnih čvorova nakon неоадъювантной таксана osnovi i her2-таргетной terapija. Метастатический rak dojke (mbk)kadcyla je uvedena, kao i u obliku монопрепарата, indiciran za liječenje odraslih bolesnika s her2 pozitivnim, неоперабельным bolesnika s местнораспространенным ili metastatskih tumora dojke, koje su prethodno dobili трастузумаб i таксана, odvojeno ili u kombinaciji. pacijenti moraju imati:dobijala ranije terapija lokalno-održao ili метастатического bolesti, ordeveloped recidiva bolesti tijekom ili u roku od šest mjeseci nakon završetka adjuvantne terapije.
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
pixuvri
les laboratoires servier - pixantron dimaleat - limfom, non-hodgkin - antineoplastična sredstva - pixuvri je indiciran kao monoterapija za liječenje odraslih bolesnika s višestrukim recidiviranim ili refraktornim agresivnim ne-hodgkin b-staničnim limfomima (nhl). prednost pixantronskog liječenja nije utvrđena u bolesnika kada se koristi kao peta linija ili veća kemoterapija u bolesnika koji su vatrometni na posljednju terapiju.
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplazme dojki - antineoplastična sredstva - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
Hrvatska -
hrvatski -
HALMED (Agencija za lijekove i medicinske proizvode)
paklitaksel kabi 6 mg/ml koncentrat za otopinu za infuziju
fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - paklitaksel - koncentrat za otopinu za infuziju - urbroj: svaka bočica sadrži 6 mg paklitaksela po 1 ml koncentrata za otopinu za infuziju
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
zolsketil pegylated liposomal
accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.
Europska Unija -
hrvatski -
EMA (European Medicines Agency)
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doksorubicin hidroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).